417 related articles for article (PubMed ID: 11956270)
1. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
[TBL] [Abstract][Full Text] [Related]
2. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
[TBL] [Abstract][Full Text] [Related]
3. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
5. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
7. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
8. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
9. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
11. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
[TBL] [Abstract][Full Text] [Related]
12. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
Sigal BM; Munoz DF; Kurian AW; Plevritis SK
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1066-77. PubMed ID: 22556274
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
[TBL] [Abstract][Full Text] [Related]
14. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.
Tengs TO; Winer EP; Paddock S; Aguilar-Chavez O; Berry DA
Med Decis Making; 1998; 18(4):365-75. PubMed ID: 10372578
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
[TBL] [Abstract][Full Text] [Related]
16. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
17. A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers.
Abdollahian M; Das TK
IEEE J Biomed Health Inform; 2015 Mar; 19(2):720-7. PubMed ID: 24771600
[TBL] [Abstract][Full Text] [Related]
18. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
19. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
20. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
Kurian AW; Sigal BM; Plevritis SK
J Clin Oncol; 2010 Jan; 28(2):222-31. PubMed ID: 19996031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]